High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

Publication Name: Annals of Oncology

Author(s): Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators.

BACKGROUND: To investigate the correlation of TargetPrint with local and central immunohistochemistry/fluorescence in situ hybridization assessment of estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2) in the first 800 patients enrolled in the MINDACT trial. PATIENTS … Continued

Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments

Publication Name: Poster, SABCS 2008

Author(s): Paul Roepman, Hugo Horlings, Oscar Krijgsman, Jolien Bueno-de-Mesquita, Richard Bender, Sabine Linn, Annuska Glas and Marc van de Vijver

In breast cancer patients the level of expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 is predictive for prognosis and/or treatment response. However, differences in assessment methods and interpretation can substantially affect the accuracy and reproducibility of the … Continued